M. Radhi, Fatima Malik Abood AL-Rubea, Iman Fadhel Abdul-Hussin, N. Hindi, R. AL-Jubori
tlooto Summary
The coronavirus disease-19 (COVID-19) signs mostly include fever and respiratory symptoms, and ACE2 is the SARS TMPRSS2 for spike (S) protein receptor for initiation of infection; hence, it is a target for pharmacological intervention.
Abstract
The coronavirus disease-19 (COVID-19) signs mostly include fever and respiratory symptoms (unusual viral pneumonia by SARS-Coronaviruses 2 or SARS-CoV-2). The Receptor-Binding Domain (RBD) of COVID-19 and SARS-CoV are similar, causing cross-reactivity of anti-SARSCoV antibodies with associated spike protein, exerting promising implications for rapid development of vaccines and therapeutic antibodies against COVID-19. ACE2 is the SARS TMPRSS2 for spike (S) protein receptor for initiation of infection;hence, it is a target for pharmacological intervention. Furthermore, designing novel monoclonal antibodies binding specifically to COVID-19 RBD is essential. A viral S proteins (TMPRSS2) was proposed for clinical use by blocking the viral intake by cell.Copyright © 2020, Health Biotechnology and Biopharma. All rights reserved.
Citation format
RADHI, M., et al. Novel coronavirus disease-19:an overviwe of pathogenesis, health influences and measures. Health Biotechnology and Biopharma, 2020, 4(2).